More on XENE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $60.22 |
|
|||
| Open | $60.48 | ||||
| 52 Wk High | $9.75 | ||||
| 52 Wk Low | $5.65 | ||||
| Day High | $61.16 | ||||
| Day Low | $59.54 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 418,793 | ||||
- Form 144 Xenon Pharmaceuticals Filed by: KENNEY CHRISTOPHER JOHN
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xenon to present phase 3 azetukalner data at European Epilepsy Congress
- Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
- Form 4 Xenon Pharmaceuticals For: Aug 11 Filed by: GANNON STEVEN
- Form 144 Xenon Pharmaceuticals Filed by: GANNON STEVEN
- Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
- H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)
- Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: FMR LLC
- Xenon Pharmaceuticals (XENE) PT Lowered to $81 at RBC Capital
Entities mentioned with XENE
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Jefferies & Co | View Related Stories »
- Stifel | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
